How significant is the association between metabolic syndrome and prevalence of colorectal neoplasia?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F16%3A10328018" target="_blank" >RIV/00216208:11110/16:10328018 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/16:00088892 RIV/61383082:_____/16:00000205

Výsledek na webu

<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5037079/pdf/WJG-22-8103.pdf" target="_blank" >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5037079/pdf/WJG-22-8103.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3748/wjg.v22.i36.8103" target="_blank" >10.3748/wjg.v22.i36.8103</a>

Jazyk výsledku

angličtina

Název v původním jazyce

How significant is the association between metabolic syndrome and prevalence of colorectal neoplasia?

Popis výsledku v původním jazyce

The incidence and prevalence of metabolic syndrome (MS) and colorectal cancer (CRC) has been rising in developed countries. The association between these two diseases has been widely studied and reported. Less evidence is available about the relationship between MS and CRC precancerous lesions (adenomatous polyps, adenomas). The aim of this paper is to present an overview of our scientific understanding of that topic and its implication in clinical practice. One of the principal goals of current CRC secondary prevention efforts is to detect and remove the precancerous lesions in individuals with an average CRC risk to prevent the development of invasive cancer. MS is not currently considered a high-risk CRC factor and is therefore not included in the guidelines of organized screening programs. However, in light of growing scientific evidence, the approach to patients with MS should be changed. Metabolic risk factors for the development of adenomas and cancers are the same - obesity, impaired glucose tolerance, dyslipidemia, hypertension, cardiovascular diseases and diabetes mellitus type 2. Therefore, the key issue in the near future is the development of a simple scoring system, easy to use in clinical practice, which would identify individuals with high metabolic risk of colorectal neoplasia and would be used for individual CRC secondary prevention strategies. Currently, such scoring systems have been published based on Asian (Asia-Pacific Colorectal Screening Score; APCS) and Polish populations.

Název v anglickém jazyce

How significant is the association between metabolic syndrome and prevalence of colorectal neoplasia?

Popis výsledku anglicky

The incidence and prevalence of metabolic syndrome (MS) and colorectal cancer (CRC) has been rising in developed countries. The association between these two diseases has been widely studied and reported. Less evidence is available about the relationship between MS and CRC precancerous lesions (adenomatous polyps, adenomas). The aim of this paper is to present an overview of our scientific understanding of that topic and its implication in clinical practice. One of the principal goals of current CRC secondary prevention efforts is to detect and remove the precancerous lesions in individuals with an average CRC risk to prevent the development of invasive cancer. MS is not currently considered a high-risk CRC factor and is therefore not included in the guidelines of organized screening programs. However, in light of growing scientific evidence, the approach to patients with MS should be changed. Metabolic risk factors for the development of adenomas and cancers are the same - obesity, impaired glucose tolerance, dyslipidemia, hypertension, cardiovascular diseases and diabetes mellitus type 2. Therefore, the key issue in the near future is the development of a simple scoring system, easy to use in clinical practice, which would identify individuals with high metabolic risk of colorectal neoplasia and would be used for individual CRC secondary prevention strategies. Currently, such scoring systems have been published based on Asian (Asia-Pacific Colorectal Screening Score; APCS) and Polish populations.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FE - Ostatní obory vnitřního lékařství

OECD FORD obor

—

Projekt

<a href="/cs/project/NT13673" target="_blank" >NT13673: Cílený screening kolorektálního karcinomu u diabetiků 2. typu a osob s vysokým kardiovaskulárním rizikem: multicentrická prospektivní studie</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

World Journal of Gastroenterology

ISSN

1007-9327

e-ISSN

—

Svazek periodika

22

Číslo periodika v rámci svazku

36

Stát vydavatele periodika

CN - Čínská lidová republika

Počet stran výsledku

9

Strana od-do

8103-8111

Kód UT WoS článku

000383982700005

EID výsledku v databázi Scopus

2-s2.0-84991089523